IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login
Users Online :1662
Small font sizeDefault font sizeIncrease font size
About Editorial Board Ahead of print Current Issue Archive Search Instructions Announcement Etcetera Contact Advertise
Navigate Here
  »   My Preferences 
  »   Manuscript submission
 Back To Article

  Reader Comments

Year : 2021 | Volume:  53 | Issue Number:  3

SHORT COMMUNICATION

Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors

Cure Erkan, Kucuk Adem, Cure Medine Cumhur

Add Your Comments
 
No one has added comments on this article. Click here to add your remarks


 

 

 
Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow